Subtle variations in Pten dose determine cancer susceptibility (original) (raw)

Accession codes

Accessions

Gene Expression Omnibus

NCBI Reference Sequence

References

  1. Friend, S.H. Alfred Knudson: the importance of a visionary who enables scientists. Genes Chromosom. Cancer 38, 326–328 (2003).
    Article Google Scholar
  2. Trotman, L.C. et al. Pten dose dictates cancer progression in the prostate. PLoS Biol. 1, E59 (2003).
    Article Google Scholar
  3. Yan, H. et al. Small changes in expression affect predisposition to tumorigenesis. Nat. Genet. 30, 25–26 (2002).
    Article CAS Google Scholar
  4. Salmena, L., Carracedo, A. & Pandolfi, P.P. Tenets of PTEN tumor suppression. Cell 133, 403–414 (2008).
    Article CAS Google Scholar
  5. Knudson, A.G. Two genetic hits (more or less) to cancer. Nat. Rev. Cancer 1, 157–162 (2001).
    Article CAS Google Scholar
  6. Knudson, A.G. Hereditary cancer: two hits revisited. J. Cancer Res. Clin. Oncol. 122, 135–140 (1996).
    Article CAS Google Scholar
  7. Ma, L. et al. Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Genes Dev. 19, 1779–1786 (2005).
    Article CAS Google Scholar
  8. Di Cristofano, A., Pesce, B., Cordon-Cardo, C. & Pandolfi, P.P. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19, 348–355 (1998).
    Article CAS Google Scholar
  9. Venkatachalam, S. et al. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J. 17, 4657–4667 (1998).
    Article CAS Google Scholar
  10. Di Cristofano, A. & Pandolfi, P.P. The multiple roles of PTEN in tumor suppression. Cell 100, 387–390 (2000).
    Article CAS Google Scholar
  11. Suzuki, A. et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. 8, 1169–1178 (1998).
    Article CAS Google Scholar
  12. Podsypanina, K. et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl. Acad. Sci. USA 96, 1563–1568 (1999).
    Article CAS Google Scholar
  13. Morita, M. et al. HLF/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin. EMBO J. 22, 1134–1146 (2003).
    Article CAS Google Scholar
  14. McDevitt, M.A., Shivdasani, R.A., Fujiwara, Y., Yang, H. & Orkin, S.H.A. “Knockdown” mutation created by _cis_-element gene targeting reveals the dependence of erythroid cell maturation on the level of transcription factor GATA-1. Proc. Natl. Acad. Sci. USA 94, 6781–6785 (1997).
    Article CAS Google Scholar
  15. Di Cristofano, A. et al. Impaired Fas response and autoimmunity in Pten+/− mice. Science 285, 2122–2125 (1999).
    Article CAS Google Scholar
  16. Hong, F. et al. RankProd: a bioconductor package for detecting differentially expressed genes in meta-analysis. Bioinformatics 22, 2825–2827 (2006).
    Article CAS Google Scholar
  17. Saal, L.H. et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 65, 2554–2559 (2005).
    Article CAS Google Scholar
  18. Bose, S. et al. Reduced expression of PTEN correlates with breast cancer progression. Hum. Pathol. 33, 405–409 (2002).
    Article CAS Google Scholar
  19. Richardson, A.L. et al. X-chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9, 121–132 (2006).
    Article CAS Google Scholar
  20. Carver, B.S. et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat. Genet. 41, 619–624 (2009).
    Article CAS Google Scholar
  21. Trotman, L.C. et al. Identification of a tumour suppressor network opposing nuclear Akt function. Nature 441, 523–527 (2006).
    Article CAS Google Scholar

Download references

Acknowledgements

We thank Z. Chen for help with genotyping and characterization of the Pten hypomorphic mutant mice. This study was supported, in part, by US National Cancer Institute grants (SPORE 92629 in Prostate Cancer, MMHCC CA-84292 and RO1 CA-82328). A.C. was supported by a long-term European Molecular Biology Organization fellowship.

Author information

Author notes

  1. Lloyd C Trotman
    Present address: Current address: Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, USA.,
  2. Arkaitz Carracedo and John G Clohessy: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Medicine, Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Andrea Alimonti, Arkaitz Carracedo, John G Clohessy, Caterina Nardella, Ainara Egia, Leonardo Salmena, Katia Sampieri, William J Haveman & Pier Paolo Pandolfi
  2. Department of Pathology, Beth Israel Deaconess Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Andrea Alimonti, Arkaitz Carracedo, John G Clohessy, Caterina Nardella, Ainara Egia, Leonardo Salmena, Katia Sampieri, William J Haveman & Pier Paolo Pandolfi
  3. Cancer Biology and Genetics Program, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    Andrea Alimonti, Arkaitz Carracedo, John G Clohessy, Lloyd C Trotman, Caterina Nardella, Ainara Egia, Leonardo Salmena, William J Haveman & Pier Paolo Pandolfi
  4. Department of Pathology, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    Andrea Alimonti, Arkaitz Carracedo, John G Clohessy, Caterina Nardella, Ainara Egia, Leonardo Salmena, William J Haveman, Edi Brogi & Pier Paolo Pandolfi
  5. Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA
    Andrea L Richardson
  6. Faculty of Arts and Sciences (FAS), Center for Systems Biology, Harvard University, Cambridge, Massachusetts, USA
    Jiangwen Zhang

Authors

  1. Andrea Alimonti
    You can also search for this author inPubMed Google Scholar
  2. Arkaitz Carracedo
    You can also search for this author inPubMed Google Scholar
  3. John G Clohessy
    You can also search for this author inPubMed Google Scholar
  4. Lloyd C Trotman
    You can also search for this author inPubMed Google Scholar
  5. Caterina Nardella
    You can also search for this author inPubMed Google Scholar
  6. Ainara Egia
    You can also search for this author inPubMed Google Scholar
  7. Leonardo Salmena
    You can also search for this author inPubMed Google Scholar
  8. Katia Sampieri
    You can also search for this author inPubMed Google Scholar
  9. William J Haveman
    You can also search for this author inPubMed Google Scholar
  10. Edi Brogi
    You can also search for this author inPubMed Google Scholar
  11. Andrea L Richardson
    You can also search for this author inPubMed Google Scholar
  12. Jiangwen Zhang
    You can also search for this author inPubMed Google Scholar
  13. Pier Paolo Pandolfi
    You can also search for this author inPubMed Google Scholar

Contributions

A.A., L.C.T. and P.P.P. conceived and designed the experiments. A.A., A.C., J.G.C., C.N., A.E., L.S., K.S. and W.J.H. performed the experiments. A.A., A.C., J.G.C., C.N., L.S., E.B., A.L.R., J.Z. and P.P.P. analyzed the data. A.A., A.C., J.G.C. and P.P.P. wrote the paper.

Corresponding author

Correspondence toPier Paolo Pandolfi.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Rights and permissions

About this article

Cite this article

Alimonti, A., Carracedo, A., Clohessy, J. et al. Subtle variations in Pten dose determine cancer susceptibility.Nat Genet 42, 454–458 (2010). https://doi.org/10.1038/ng.556

Download citation